Re-visiting the call for translation of cancer survivorship research: collaborative multidisciplinary approaches to improve translation and dissemination.
Cancer
Cancer survivorship
Dissemination science
Translational science
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
14
12
2022
accepted:
26
09
2023
medline:
1
12
2023
pubmed:
14
11
2023
entrez:
13
11
2023
Statut:
ppublish
Résumé
The number of cancer survivors in the US is dramatically increasing and survivors are living longer, making the ongoing care and quality of life in this growing population an important public health issue. Although there has been significant progress in cancer survivorship research, gaps in translating this research to real-world settings to benefit survivors remain. The number and type of cancer survivorship research activities in past and current projects were gathered in reports and work plans from the Cancer Prevention and Control Research Network (CPCRN). Additionally, current cross-center projects were aligned with common constructs in dissemination and implementation science to provide a narrative review of progress on translational research. A review of historical activities in the CPCRN indicates that there has been consistent engagement in survivorship from multiple institutions over the last decade, generating 84 grants, 168 papers and 162 presentations. The current membership of the Survivorship Workgroup includes multiple disciplines and all 8 participating institutions. Together these Workgroup members have developed 6 projects, all of which address multiple domains in translational research such as feasibility, practicality, and organizational and cultural factors that affect implementation. This review of past and ongoing activities in the CPCRN suggests that survivorship has been a consistent priority including the translation of evidence-based approaches into practice. Specific gaps in the translational research agenda that could be the focus of future investigations by Workgroup members and others include the practical and logistic aspects of interventions such as cost and policy.
Sections du résumé
BACKGROUND
BACKGROUND
The number of cancer survivors in the US is dramatically increasing and survivors are living longer, making the ongoing care and quality of life in this growing population an important public health issue. Although there has been significant progress in cancer survivorship research, gaps in translating this research to real-world settings to benefit survivors remain.
METHODS
METHODS
The number and type of cancer survivorship research activities in past and current projects were gathered in reports and work plans from the Cancer Prevention and Control Research Network (CPCRN). Additionally, current cross-center projects were aligned with common constructs in dissemination and implementation science to provide a narrative review of progress on translational research.
RESULTS
RESULTS
A review of historical activities in the CPCRN indicates that there has been consistent engagement in survivorship from multiple institutions over the last decade, generating 84 grants, 168 papers and 162 presentations. The current membership of the Survivorship Workgroup includes multiple disciplines and all 8 participating institutions. Together these Workgroup members have developed 6 projects, all of which address multiple domains in translational research such as feasibility, practicality, and organizational and cultural factors that affect implementation.
CONCLUSIONS
CONCLUSIONS
This review of past and ongoing activities in the CPCRN suggests that survivorship has been a consistent priority including the translation of evidence-based approaches into practice. Specific gaps in the translational research agenda that could be the focus of future investigations by Workgroup members and others include the practical and logistic aspects of interventions such as cost and policy.
Identifiants
pubmed: 37957530
doi: 10.1007/s10552-023-01809-5
pii: 10.1007/s10552-023-01809-5
pmc: PMC10689512
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-208Subventions
Organisme : CDC HHS
ID : U48 DP006399
Pays : United States
Organisme : CDC HHS
ID : U48 DP006400
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006399
Pays : United States
Organisme : CDC HHS
ID : U48 DP006413
Pays : United States
Organisme : CDC HHS
ID : U48 DP006389
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
J Cancer Surviv. 2023 Jun 10;:
pubmed: 37301792
CA Cancer J Clin. 2022 May;72(3):230-262
pubmed: 35294043
Am J Prev Med. 2015 Dec;49(6 Suppl 5):S470-6
pubmed: 26590641
CA Cancer J Clin. 2020 Jul;70(4):245-271
pubmed: 32515498
J Natl Cancer Inst. 2014 Sep 22;106(11):
pubmed: 25249551
Cancer Causes Control. 2023 Apr;34(4):371-387
pubmed: 36781715
Am J Prev Med. 2021 Jun;60(6):877-882
pubmed: 33785276
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2093-8
pubmed: 21980017
J Natl Cancer Inst. 2019 Nov 1;111(11):1120-1130
pubmed: 31095326
J Cancer Surviv. 2013 Sep;7(3):425-38
pubmed: 23609522
J Clin Oncol. 2022 Aug 1;40(22):2491-2507
pubmed: 35576506
Am J Prev Med. 2021 May;60(5):732-736
pubmed: 33663935
Prev Chronic Dis. 2011 Mar;8(2):A46
pubmed: 21324260